## Tanya L Hoskin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10469895/publications.pdf

Version: 2024-02-01

76326 102487 4,979 128 40 66 citations h-index g-index papers 128 128 128 5752 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Temporal Trends in Infective Endocarditis. JAMA - Journal of the American Medical Association, 2005, 293, 3022.	7.4	309
2	The Microbiome of Aseptically Collected Human Breast Tissue in Benign and Malignant Disease. Scientific Reports, 2016, 6, 30751.	3.3	299
3	Common iliac artery aneurysm: Expansion rate and results of open surgical and endovascular repair. Journal of Vascular Surgery, 2008, 47, 1203-1211.e2.	1.1	181
4	Factors affecting outcomes of open surgical repair of pararenal aortic aneurysms: A 10-year experience. Journal of Vascular Surgery, 2006, 43, 921-928.e1.	1.1	171
5	Early complications and long-term outcome after open surgical treatment of popliteal artery aneurysms: Is exclusion with saphenous vein bypass still the gold standard?. Journal of Vascular Surgery, 2007, 45, 706-715.e1.	1.1	170
6	Dysphagia in Inflammatory Myopathy: Clinical Characteristics, Treatment Strategies, and Outcome in 62 Patients. Mayo Clinic Proceedings, 2007, 82, 441-447.	3.0	161
7	Open repair of juxtarenal aortic aneurysms (JAA) remains a safe option in the era of fenestrated endografts. Journal of Vascular Surgery, 2008, 47, 695-701.	1.1	159
8	Perioperative complications and early outcome after endovascular and open surgical repair of abdominal aortic aneurysms. Journal of Vascular Surgery, 2004, 39, 497-505.	1.1	147
9	Contralateral Prophylactic Mastectomy is Associated with a Survival Advantage in High-Risk Women with a Personal History of Breast Cancer. Annals of Surgical Oncology, 2010, 17, 2702-2709.	1.5	135
10	The Impact of Valve Surgery on 6-Month Mortality in Left-Sided Infective Endocarditis. Circulation, 2007, 115, 1721-1728.	1.6	119
11	Breast Cancer-Related Lymphedema Risk is Related to Multidisciplinary Treatment and Not Surgery Alone: Results from a Large Cohort Study. Annals of Surgical Oncology, 2017, 24, 2972-2980.	1.5	118
12	Expanded Indications and Improved Outcomes for Nipple-Sparing Mastectomy Over Time. Annals of Surgical Oncology, 2015, 22, 3317-3323.	1.5	116
13	Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes. Annals of Surgical Oncology, 2018, 25, 2241-2248.	1.5	99
14	Contralateral Prophylactic Mastectomy: Long-Term Consistency of Satisfaction and Adverse Effects and the Significance of Informed Decision-Making, Quality of Life, and Personality Traits. Annals of Surgical Oncology, 2011, 18, 3110-3116.	1.5	98
15	Association of Low Nodal Positivity Rate Among Patients With <i>ERBB2</i> Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy. JAMA Surgery, 2018, 153, 1120.	4.3	96
16	Dysphagia in Inclusion Body Myositis. American Journal of Physical Medicine and Rehabilitation, 2008, 87, 883-889.	1.4	94
17	Safety and technical success of methylene blue dye for lymphatic mapping in breast cancer. American Journal of Surgery, 2008, 196, 228-233.	1.8	76
18	Most Patients with Abdominal Aortic Aneurysm Are Not Suitable for Endovascular Repair Using Currently Approved Bifurcated Stent-Grafts. Vascular and Endovascular Surgery, 2004, 38, 401-412.	0.7	73

#	Article	IF	Citations
19	Multivariate model to identify women at low risk of cancer upgrade after a core needle biopsy diagnosis of atypical ductal hyperplasia. Breast Cancer Research and Treatment, 2017, 164, 295-304.	2.5	68
20	CT Fluoroscopy–guided Biopsy of the Lung or Upper Abdomen with a Breath-hold Monitoring and Feedback System: A Prospective Randomized Controlled Clinical Trial. Radiology, 2005, 237, 701-708.	7.3	67
21	Immune cell quantitation in normal breast tissue lobules with and without lobulitis. Breast Cancer Research and Treatment, 2014, 144, 539-549.	2.5	65
22	Adolescents and Young Adults with Breast Cancer have More Aggressive Disease and Treatment Than Patients in Their Forties. Annals of Surgical Oncology, 2019, 26, 3920-3930.	1.5	65
23	Histologic findings in normal breast tissues: comparison to reduction mammaplasty and benign breast disease tissues. Breast Cancer Research and Treatment, 2012, 133, 169-177.	2.5	64
24	Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer. Journal of Clinical Oncology, 2020, 38, 1409-1418.	1.6	64
25	Randomized Controlled Trial to Reduce Bacterial Colonization of Surgical Drains After Breast and Axillary Operations. Annals of Surgery, 2013, 258, 240-247.	4.2	63
26	Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes. Annals of Surgical Oncology, 2017, 24, 3067-3072.	1.5	63
27	Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study. Annals of Surgical Oncology, 2017, 24, 418-424.	1.5	58
28	Incidence of Clinically Significant Seroma after Breast and Axillary Surgery. Journal of the American College of Surgeons, 2009, 208, 148-150.	0.5	56
29	Impact of Reconstruction and Reoperation on Long-Term Patient-Reported Satisfaction After Contralateral Prophylactic Mastectomy. Annals of Surgical Oncology, 2015, 22, 401-408.	1.5	55
30	Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2018, 25, 2596-2602.	1.5	55
31	Oncologic Outcomes of Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer. Annals of Surgical Oncology, 2020, 27, 4795-4801.	1.5	55
32	Predicting Nodal Positivity in Women 70ÂYears of Age and Older with Hormone Receptor-Positive Breast Cancer to Aid Incorporation of a Society of Surgical Oncology Choosing Wisely Guideline into Clinical Practice. Annals of Surgical Oncology, 2017, 24, 2881-2888.	1.5	52
33	National Trends in the Use of Neoadjuvant Chemotherapy for Hormone Receptor-Negative Breast Cancer: A National Cancer Data Base Study. Annals of Surgical Oncology, 2017, 24, 1242-1250.	1.5	51
34	Macrophagic "Crown-like Structures―Are Associated with an Increased Risk of Breast Cancer in Benign Breast Disease. Cancer Prevention Research, 2018, 11, 113-119.	1.5	50
35	Risk Factors Associated with Breast Lymphedema. Annals of Surgical Oncology, 2014, 21, 1202-1208.	1.5	48
36	Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women. Cancer, 2016, 122, 2971-2978.	4.1	48

3

#	Article	IF	CITATIONS
37	A prospective study of breast lymphedema: frequency, symptoms, and quality of life. Breast Cancer Research and Treatment, 2012, 134, 915-922.	2.5	47
38	Surgical Site Infection after Breast Surgery: Impact of 2010 CDC Reporting Guidelines. Annals of Surgical Oncology, 2012, 19, 4099-4103.	1.5	46
39	Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer. Annals of Surgical Oncology, 2016, 23, 3232-3238.	1.5	46
40	Alterations in the Immune Cell Composition in Premalignant Breast Tissue that Precede Breast Cancer Development. Clinical Cancer Research, 2017, 23, 3945-3952.	7.0	46
41	Flat Epithelial Atypia on Core Biopsy and Upgrade to Cancer: a Systematic Review and Meta-Analysis. Annals of Surgical Oncology, 2017, 24, 3549-3558.	1.5	46
42	Effect of Surgery Type on Time to Adjuvant Chemotherapy and Impact of Delay on Breast Cancer Survival: A National Cancer Database Analysis. Annals of Surgical Oncology, 2019, 26, 3240-3249.	1.5	46
43	Use of immediate breast reconstruction and choice for contralateral prophylactic mastectomy. Surgery, 2016, 159, 1199-1209.	1.9	39
44	Bioinformatics and DNA-extraction strategies to reliably detect genetic variants from FFPE breast tissue samples. BMC Genomics, 2019, 20, 689.	2.8	37
45	Has the Time Come to Stop Surgical Staging of the Axilla for All Women Age 70ÂYears or Older with Hormone Receptor-Positive Breast Cancer?. Annals of Surgical Oncology, 2017, 24, 614-617.	1.5	35
46	Endovascular Repair of Abdominal Aortic Aneurysms: Initial Experience With 100 Consecutive Patients. Mayo Clinic Proceedings, 2003, 78, 1234-1242.	3.0	34
47	Sentinel node positive breast cancer patients who do not undergo axillary dissection: Are they different?. Surgery, 2008, 143, 641-647.	1.9	31
48	Assessment of the performance of the Stanford Online Calculator for the prediction of nonsentinel lymph node metastasis in sentinel lymph nodeâ€positive breast cancer patients. Cancer, 2009, 115, 4064-4070.	4.1	31
49	MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. Academic Radiology, 2022, 29, S145-S154.	2.5	31
50	Conclusion about the association between valve surgery and mortality in an infective endocarditis cohort changed after adjusting for survivor bias. Journal of Clinical Epidemiology, 2010, 63, 130-135.	5.0	30
51	Mastectomy and immediate breast reconstruction in the elderly: Trends and outcomes. Surgery, 2019, 166, 709-714.	1.9	30
52	Natural history of age-related lobular involution and impact on breast cancer risk. Breast Cancer Research and Treatment, 2016, 155, 423-430.	2.5	29
53	Brief Interdisciplinary Treatment Program for Fibromyalgia. American Journal of Physical Medicine and Rehabilitation, 2010, 89, 115-124.	1.4	28
54	Mastectomy and Immediate Breast Reconstruction for Cancer in the Elderly: A National Cancer Data Base Study. Journal of the American College of Surgeons, 2017, 224, 895-905.	0.5	26

#	Article	IF	Citations
55	Outcomes of > 1300 Nipple-Sparing Mastectomies with Immediate Reconstruction: The Impact of Expanding Indications on Complications. Annals of Surgical Oncology, 2019, 26, 3115-3123.	1.5	26
56	Intermittent-Mode CT Fluoroscopy–guided Biopsy of the Lung or Upper Abdomen with Breath-hold Monitoring and Feedback: System Development and Feasibility. Radiology, 2003, 229, 906-912.	7.3	25
57	Impact of Neoadjuvant Chemotherapy on Nodal Disease and Nodal Surgery by Tumor Subtype. Annals of Surgical Oncology, 2018, 25, 482-493.	1.5	25
58	Lessons Learned Regarding Missing Clinical Stage in the National Cancer Database. Annals of Surgical Oncology, 2019, 26, 739-745.	1.5	24
59	Patients With Fibromyalgia Have Significant Autonomic Symptoms But Modest Autonomic Dysfunction. PM and R, 2016, 8, 425-435.	1.6	22
60	Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia. Journal of Clinical Oncology, 2018, 36, 1840-1846.	1.6	22
61	Novel Factors to Improve Prediction of Nodal Positivity in Patients with Clinical T1/T2 Breast Cancers. Annals of Surgical Oncology, 2013, 20, 3286-3293.	1.5	19
62	Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes. Clinical Breast Cancer, 2018, 18, e501-e506.	2.4	19
63	Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2â° node positive breast cancerâ€"A National Cancer Database study. Npj Breast Cancer, 2017, 3, 41.	5.2	18
64	Preoperative Prediction of Node-Negative Disease After Neoadjuvant Chemotherapy in Patients Presenting with Node-Negative or Node-Positive Breast Cancer. Annals of Surgical Oncology, 2017, 24, 2518-2525.	1.5	17
65	Predicting Non-sentinel Lymph Node Metastases in Patients with a Positive Sentinel Lymph Node After Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2018, 25, 2867-2874.	1.5	17
66	Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α. Clinical Cancer Research, 2020, 26, 2986-2996.	7.0	17
67	${\sf ER\hat{I}^2}$ Expression and Breast Cancer Risk Prediction for Women with Atypias. Cancer Prevention Research, 2015, 8, 1084-1092.	1.5	16
68	Predictors of Clinical Outcome in Fibromyalgia After a Brief Interdisciplinary Fibromyalgia Treatment Program: Single Center Experience. PM and R, 2012, 4, 257-263.	1.6	15
69	Contralateral Prophylactic Mastectomy: Factors Predictive of Occult Malignancy or High-Risk Lesion and the Impact of MRI and Genetic Testing. Annals of Surgical Oncology, 2016, 23, 72-77.	1.5	14
70	Is axillary surgery beneficial for patients with adenoid cystic carcinoma of the breast?. Journal of Surgical Oncology, 2017, 116, 690-695.	1.7	14
71	Treatment Outcomes for Pleomorphic Lobular Carcinoma In Situ of the Breast. Annals of Surgical Oncology, 2018, 25, 3064-3068.	1.5	14
72	Randomized Trial of Drain Antisepsis After Mastectomy and Immediate Prosthetic Breast Reconstruction. Annals of Surgical Oncology, 2014, 21, 3240-3248.	1.5	13

#	Article	IF	CITATIONS
73	Ki-67 expression in sclerosing adenosis and adjacent normal breast terminal ductal lobular units: a nested case–control study from the Mayo Benign Breast Disease Cohort. Breast Cancer Research and Treatment, 2015, 151, 89-97.	2.5	13
74	Frequency of diagnosis of cancer orÂhigh-risk lesion at operation forÂpathologic nipple discharge. Surgery, 2015, 158, 988-995.	1.9	13
75	Effect of Primary Breast Tumor Location on Axillary Nodal Positivity. Annals of Surgical Oncology, 2018, 25, 3011-3018.	1.5	13
76	Breast cancer after prophylactic mastectomy (bilateral or contralateral prophylactic mastectomy), a clinical entity: presentation, management, and outcomes. Breast Cancer Research and Treatment, 2015, 153, 183-190.	2.5	12
77	Management of the axilla in metaplastic breast carcinoma. Gland Surgery, 2018, 7, 200-206.	1.1	11
78	Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer. Breast Cancer Research, 2020, 22, 51.	5.0	11
79	Increasing Use of Neoadjuvant Treatment for T1 and T2 HER2-Positive Tumors. Annals of Surgical Oncology, 2015, 22, 3369-3375.	1.5	10
80	Validation of the CPSÂ+ÂEG Staging System for Disease-Specific Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2016, 23, 3206-3211.	1.5	10
81	NanoString-based breast cancer risk prediction for women with sclerosing adenosis. Breast Cancer Research and Treatment, 2017, 166, 641-650.	2.5	10
82	Changes in Management Strategy and Impact of Neoadjuvant Therapy on Extent of Surgery in Invasive Lobular Carcinoma of the Breast: Analysis of the National Cancer Database (NCDB). Annals of Surgical Oncology, 2021, 28, 5867-5877.	1.5	10
83	Noninvasive measurement of aortic aneurysm sac tension with vibrometry. Journal of Vascular Surgery, 2005, 42, 963-971.	1.1	9
84	Factors Influencing Use of Hormone Therapy for Ductal Carcinoma In Situ: A National Cancer Database Study. Annals of Surgical Oncology, 2017, 24, 2989-2998.	1.5	9
85	Outcomes and feasibility of nipple-sparing mastectomy for node-positive breast cancer Patients. American Journal of Surgery, 2017, 213, 810-813.	1.8	9
86	Breast Cancer Risk and Use of Nonsteroidal Anti-inflammatory Agents After a Benign Breast Biopsy. Cancer Prevention Research, 2020, 13, 967-976.	1.5	9
87	Upgrade at excisional biopsy after a core needle biopsy diagnosis of classic lobular carcinoma in situ. Surgery, 2021, 169, 644-648.	1.9	9
88	Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer. Npj Breast Cancer, 2022, 8, 20.	5 <b>.</b> 2	9
89	The breast tissue microbiome, stroma, immune cells and breast cancer. Neoplasia, 2022, 27, 100786.	5.3	9
90	Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67. Annals of Surgical Oncology, 2022, 29, 5747-5756.	1.5	9

#	Article	IF	CITATIONS
91	The Effect of Grape Seed Extract on Estrogen Levels of Postmenopausal Women: A Pilot Study. Journal of Dietary Supplements, 2014, 11, 184-197.	2.6	8
92	Contemporary operative management of T4 breast cancer. Surgery, 2016, 160, 1059-1069.	1.9	8
93	Contralateral Axillary Metastases in Breast Cancer: Stage IV Disease or a Locoregional Event?. American Surgeon, 2019, 85, 1391-1396.	0.8	8
94	Contemporary Axillary Management in cT1–2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database. Annals of Surgical Oncology, 2022, 29, 4740-4749.	1.5	8
95	Contralateral Prophylactic Mastectomy for Women with T4 Locally Advanced Breast Cancer. Annals of Surgical Oncology, 2016, 23, 3365-3370.	1.5	7
96	Longitudinal stability of fibromyalgia symptom clusters. Arthritis Research and Therapy, 2018, 20, 37.	3.5	7
97	Simple Prediction Models for Breast Cancer Patients with Solitary Positive Sentinel Nodes-are they Valid?. Breast Journal, 2009, 15, 610-614.	1.0	6
98	Propensity score analysis with a time-dependent intervention is an acceptable although not an optimal analytical approach when treatment selection bias and survivor bias coexist. Journal of Clinical Epidemiology, 2010, 63, 139-140.	5.0	6
99	Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy. Annals of Surgical Oncology, 2021, 28, 8729-8739.	1.5	6
100	Automated quantification of levels of breast terminal duct lobular (TDLU) involution using deep learning. Npj Breast Cancer, 2022, 8, 13.	5.2	6
101	Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HERâ€2 positive patients presenting with clinically nodeâ€negative disease. Journal of Surgical Oncology, 2015, 112, 453-457.	1.7	5
102	CD56+ immune cell infiltration and MICA are decreased in breast lobules with fibrocystic changes. Breast Cancer Research and Treatment, 2018, 167, 649-658.	2.5	5
103	Sentinel Lymph Node Removal After Neoadjuvant Chemotherapy in Clinically Node-Negative Patients: When to Stop?. Annals of Surgical Oncology, 2021, 28, 888-893.	1.5	5
104	Perceived dyscognition reported by patients with fibromyalgia. Clinical and Experimental Rheumatology, 2016, 34, S48-54.	0.8	5
105	Contralateral Axillary Metastases in Breast Cancer: Stage IV Disease or a Locoregional Event?. American Surgeon, 2019, 85, 1391-1396.	0.8	5
106	Cytotoxic T cell depletion with increasing epithelial abnormality in women with benign breast disease. Breast Cancer Research and Treatment, 2020, 180, 55-61.	2.5	4
107	Performance and Clinical Utility of Models Predicting Eradication of Nodal Disease in Patients with Clinically Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy by Tumor Biology. Annals of Surgical Oncology, 2020, 27, 4678-4686.	1.5	4
108	Decreasing the Use of Sentinel Lymph Node Surgery in Women Older than 70 Years with Hormone Receptor-Positive Breast Cancer and the Impact on Adjuvant Radiation and Hormonal Therapy. Annals of Surgical Oncology, 2021, 28, 8766-8774.	1.5	4

7

#	Article	IF	CITATIONS
109	Use of the Twelve-Gene Recurrence Score for Ductal Carcinoma in Situ and Its Influence on Receipt of Adjuvant Radiation and Hormonal Therapy. Annals of Surgical Oncology, 2021, 28, 4294-4303.	1.5	4
110	Predicting Four or More Metastatic Axillary Lymph Nodes in Patients with Sentinel Node-Positive Breast Cancer: Assessment of Existent Risk Scores. Annals of Surgical Oncology, 2010, 17, 2884-2891.	1.5	3
111	Widespread Non-Canonical Epigenetic Modifications in MMTV-NeuT Breast Cancer. Neoplasia, 2015, 17, 348-357.	5.3	3
112	Evaluation of the Aromatase Inhibition Potential of Freeze-Dried Grape Powder. Journal of Dietary Supplements, 2015, 12, 373-382.	2.6	2
113	ASO Author Reflections: A Statistical Caution Regarding Missing Clinical Stage in the National Cancer Database. Annals of Surgical Oncology, 2019, 26, 569-570.	1.5	2
114	Inflammatory Breast Cancer: Durable Breast Cancer-Specific Survival for HER2-Positive Patients with a Pathologic Complete Response to Neoadjuvant Therapy. Annals of Surgical Oncology, 2022, 29, 5383-5386.	1,5	2
115	Factors Influencing Non-sentinel Lymph Node Involvement in Patients with Positive Sentinel Lymph Node(s) After Neoadjuvant Chemotherapy for Breast Cancer. Annals of Surgical Oncology, 2022, 29, 7769-7778.	1.5	2
116	Using Size and Grade to Identify Women AgedÂ≥Â70ÂYears with Endocrine-Responsive Breast Cancer at Low Risk of Nodal Positivity. Annals of Surgical Oncology, 2017, 24, 557-558.	1.5	1
117	Hyaline fibrous involution of breast lobules: a histologic finding associated with germline BRCA mutation. Modern Pathology, 2019, 32, 1263-1270.	5.5	1
118	ASO Visual Abstract: Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy. Annals of Surgical Oncology, 2021, 28, 560-561.	1.5	1
119	Sexual Well-Being After Nipple-Sparing Mastectomy: Does Preservation of the Nipple Matter?. Annals of Surgical Oncology, 2022, 29, 4167-4179.	1.5	1
120	ASO Author Reflections: Axillary Management in Mastectomy Patients with Limited Nodal Burden. Annals of Surgical Oncology, 2022, , 1.	1.5	1
121	Towards defining morphologic parameters of normal parous and nulliparous breast tissues by artificial intelligence. Breast Cancer Research, 2022, 24, .	5.0	1
122	Endovascular Repair of Abdominal Aortic Aneurysms: In Response. Mayo Clinic Proceedings, 2004, 79, 570-571.	3.0	0
123	Reply to S.L. Gomez et al. Journal of Clinical Oncology, 2010, 28, e158-e158.	1.6	0
124	Postlactational involution biomarkers plasminogen and phospho-STAT3 are linked with active age-related lobular involution. Breast Cancer Research and Treatment, 2017, 166, 133-143.	2.5	0
125	Repeat Sentinel Lymph Node Surgery in Recurrent Breast Cancer: Peritumoral vs. Periareolar Injections. Clinical Breast Cancer, 2021, 21, 466-476.	2.4	0
126	Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer. Pharmacogenetics and Genomics, 2021, 31, 1-9.	1.5	0

#	Article	IF	CITATIONS
127	ASO Visual Abstract: Sexual Well-Being After Nipple-Sparing Mastectomy: Does Preservation of the Nipple Matter?. Annals of Surgical Oncology, 2022, , .	1.5	0
128	ASO Visual Abstract: Contemporary Axillary Management in cT1-2N0 Breast Cancer with $1\hat{a}\in$ "2 Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database. Annals of Surgical Oncology, 2022, , 1.	1.5	0